Application of a new serum assay for type I collagen cross-linked N- telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment

Calcified Tissue International

Volumn 63, Issue 2, 1998, Pages 102-106

  Gertz, B J ^a   Clemens, J D ^b   Holland, S D ^a   Yuan, W ^a   Greenspan, S ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Ostex International Inc   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Alendronate; N telopeptides

Indexed keywords

ALENDRONIC ACID; COLLAGEN TYPE 1;

AGED; ARTICLE; BONE TURNOVER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CROSS LINKING; DIAGNOSTIC VALUE; FEMALE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; CIRCADIAN RHYTHM; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 0031875640     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900497     Document Type: Article

References (40)

1. Eyre D (1992) New biomarkers of bone resorption (Editorial). J Clin Endocrinol Metab 74:470A-470C
2. Delmas PD (1988) Biochemical markers of bone turnover in osteoporosis. In: Riggs BL, Melton LJ III, (eds) Osteoporosis. Raven Press, New York, pp 297-316
3. Seibel MJ, Robins SP, Bilezikian JP (1992) Urinary pyridinium cross-links of collagen. Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 3:263-270.
4. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL (1983) Increase in serum bone γ-carboxyglutamic acid protein with aging in women. J Clin Invest 71:1316-1321
5. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Endocrinol Metab 67:741-748
6. Kelly PJ, Pocock NA, Sambrook PN, Eisman JA (1989) Age and menopause-related changes in indices of bone turnover. J Clin Endocrinol Metab 69:1160-1165
7. Uebelhart D, Schlemmer A, Johnansen JS, Gineyts E, Christiansen C, Delmas PD (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367-373
8. Välimäki MJ, Tähtelä R, Jones JD, Peterson JM, Riggs BL (1994) Bone resorption in healthy and osteoporotic postmenopausal women: comparison of markers for serum carboxyterminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur J Endocrinol 131:258-262
9. Schlemmer A, Hassager C, Delmas PD, Christiansen C (1994) Urinary excretion of pyridinium cross-links in healthy women: the long-term effects of menopause and oestrogen/ progesterone therapy. Clin Endocrinol 40:777-782
10. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
11. Kushida K, Takahashi M, Kawana K, Inoue T (1995) Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80:2447-2450
12. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349
13. Riggs BL, Melton LJ, O'Fallon WM (1996) Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18:197S-201S
14. Garnero P, Grimaux M, Demiaux B, Preaudat C, Sequin P, Delmas PD (1992) Measurement of serum osteocalcin with a human-specific two-site radioimmunoassay. J Bone Miner Res 7:1389-1397
15. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053
16. Hasling C, Ericksen EF, Melkko J, Risteli L, Charles P, Mosekilde L, Risteli J (1991) Effects of combined estrogengestogen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J Bone Miner Res 12:1295-1300
17. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy terminal telopeptide of type I collagen: a new marker of bone degradation. Clin Chem 39:635-640
18. Eyre DR, Koob TJ, Van Neww KP (1984) Quantitation of hydroxypyridinium cross-links in collagen by high performance liquid chromatography. Anal Biochem 137:380-388
19. Beardsworth LJ, Eyre DR, Dickson IR (1990) Changes with age in the urinary excretion of lysyl and hydroxylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5:671-676
20. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD (1990) Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96
21. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ (1991) Evaluation of urinary hydroxypyridinium cross-link measurements as resorption markers in metabolic bone disease. Eur J Clin Invest 21:310-315
22. Seyedin SM, Kung VT, Daniloff YN, Hesley R, Gomez B, Nielsen LA, Rosen HN, Zuk RF (1993) Immunoassay for urinary pyridinoline. The new marker of bone resorption. J Bone Miner Res 8:635-641
23. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
24. Prockop DJ (1964) Isotopic studies on collagen degradation and the urine excretion of hydroxyproline. J Clin Invest 43:453-460
25. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of Type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258
26. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH III, Eyre DR (1994) Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142
27. Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785
28. Bonde M, Qvist P, Fledelius C, Riss BJ, Christiansen C (1995) Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868
29. Harris ST, Gertz BJ, Eyre DR, Genant HK, Survill T, Chestnut C III (1993) The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406
30. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
31. Greenspan S, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan WY, Kher U, Gertz B (1996) Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Phys 108:230-238
32. Clemens JD, Herrick M, Singer F, Eyre DR (1997) Evidence that serum NTx (collagen type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063
33. Hanson DA, Weis MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992; 7:1251-1258
34. Schlemmer A, Hassager C, Pedersen BJ, Christiansen C (1994) Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. J Bone Miner Res 9:1883-1888
35. Eastell R, Simmons PS, Coldwell A, Assiri AM, Burritt MF, Russell RG, Riggs BL (1992) Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and aging. Clin Sci 83:375-382
36. Eastell R, Calvo MS, Burritt MF, Offord KP, Russell RGG, Riggs BL (1992) Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487-494
37. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
38. Lakatos P, Blumsohn A, Eastell R, Tarjan G, Shinoda H, Stern PH (1995) Circadian rhythm of in vitro bone-resorbing activity in human serum. J Clin Endocrinol Metab 80:3185-3190
39. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S (1995) Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 80:3304-3310
40. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696